Songwit Payapwattanawong

Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients

Guglielmo Vetere, Emerik Österlund, Mahmoud Yousef, Songwit Payapwattanawong et autres

Background Immune checkpoint inhibitors (ICIs) have limited efficacy in proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC). However, selected patients with specific metastatic patterns may derive benefit. Methods Patients with chemorefractory pMMR/MSS mCRC treated with ICI-based regimens were retrospectively identified. A …

us, it, sa (code pays fourni par la source)

Circulating tumor DNA for characterizing intratumor heterogeneity and outcomes in metastatic colorectal cancer.

Cynthia Yeung, Emerik Österlund, Guglielmo Vetere, Songwit Payapwattanawong et autres

3585 Background: Intratumor heterogeneity (ITH) drives CRC resistance, yet tissue-based assessments remain limited. ctDNA captures heterogeneity, though variable tumor fractions confound measurements. We assessed raw vs fraction-adjusted ITH in ctDNA for overall survival (OS) in metastatic CRC (mCRC). Methods: We analyzed two …

us, ca (code pays fourni par la source)

TROP2 as an actionable biomarker for anal cancer.

Mir Lim, Nejla Ozirmak Lermi, Alejandra G. Serrano, Alexey Sorokin et autres

3519 Background: Chemoimmunotherapy is standard frontline therapy for metastatic anal cancer, with no effective treatment options afterward. Mutation profiling has not yielded matched targeted therapies against anal cancer. Trophoblast cell-surface antigen 2 (TROP2) is overexpressed in other solid tumors, and TROP2 antibody-drug …

us (code pays fourni par la source)

Use of KMT2 family mutations to define a distinct epithelial-high, stromal-depleted, and interferon-active gene expression state in colorectal cancer.

Songwit Payapwattanawong, Jessica Lal, Yixin Xu, Kangyu Lin et autres

3671 Background: The KMT2A–D (MLL1–4) family of H3K4 methyltransferases are critical epigenetic regulators of enhancer landscapes and cell identity. At least one of the genes is mutated in 20-25% of colorectal cancer. Their role in shaping the tumor microenvironment (TME) remains distinct …

us (code pays fourni par la source)

Overall survival of immunotherapy versus standard of care in microsatellite stable metastatic colorectal cancer: A propensity score matched analysis of 708 patients.

Guglielmo Vetere, Emerik Österlund, Mahmoud M.G. Yousef, Songwit Payapwattanawong et autres

202 Background: Immune checkpoint inhibitors (ICIs) have limited efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC), though selected patients may derive durable benefit. We evaluated survival outcomes of MSS mCRC patients treated with ICI-based regimens versus standard of care (SOC), with …

us, it, sa (code pays fourni par la source)

Aspirin use and PI3K mutations in metastatic colorectal cancer (mCRC).

Songwit Payapwattanawong, Emerik Österlund, Guglielmo Vetere, Alisha Heather Bent et autres

189 Background: Aspirin use is established as adjuvant therapy for PIK3CA mutant (mt) stage II-III colorectal cancer, but its role in mCRC remains unclear, with conflicting findings after resection of liver metastases. We evaluated overall survival (OS) in mCRC patients by PI3K …

us (code pays fourni par la source)

Mode of presentation and symptoms of colorectal cancer (CRC) by primary tumor and molecular subgroup: A large-scale AI-powered analysis.

Guglielmo Vetere, Sebastian Correa Cautino, Mahmoud M.G. Yousef, Songwit Payapwattanawong et autres

203 Background: The mode of presentation of CRC has implications for early detection and prognosis. Our aim was to characterize presentation and symptoms at CRC diagnosis by primary location, RAS / BRAF , and mismatch repair (MMR) status at scale. Methods: A …

us, pr, it, sa (code pays fourni par la source)

Minimal residual disease (MRD) trials in colorectal cancer (CRC): An overview of a heterogeneous field.

Emerik Österlund, Guglielmo Vetere, Songwit Payapwattanawong, Kristin D Alfaro et autres

140 Background: MRD is a state where circulating tumor DNA (ctDNA) is detected without visible radiologic disease after curative intent procedures. As this is associated with a high risk of recurrence, several clinical trials are ongoing for CRC in this setting with …

us (code pays fourni par la source)

Abstract A027: Mode of presentation and symptoms at diagnosis of early- and late-onset colorectal cancer: a large retrospective AI-powered analysis

Emerik Österlund, Berta Martín-Cullell, Sebastian Correa Cautino, Mahmoud Yousef et autres

Abstract Introduction Early-onset colorectal cancer (EOCRC) is a distinct clinical entity and a rising global challenge. As presentation and symptom patterns at diagnosis have implications for early detection and prognosis, we aimed to characterize differences between EOCRC and late-onset colorectal cancer (LOCRC) …

us (code pays fourni par la source)

Body weight change in a medical supplement group in patients with early breast cancer during chemotherapy: a randomized, controlled trial

Piyawan Tienchaiananda, Meitinarth Juntong, Photcharaphon Pintasiri, Sunatee Sa-nguansai et autres

th (code pays fourni par la source)

Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study

Chanchai Charonpongsuntorn, Suebpong Tanasanvimon, Krittiya Korphaisarn, Songwit Payapwattanawong et autres

PURPOSE: Atezolizumab plus bevacizumab treatment is a first-line therapy for unresectable hepatocellular carcinoma (HCC) worldwide. The efficacy, safety, and patient-reported outcomes (PROs) of HCC in Thailand have not yet been reported. This study aimed to evaluate the efficacy, safety, and PROs of …

th (code pays fourni par la source)

MO5-3 Efficacy and patient-report outcomes of atezolizumab/ bevacizumab for unresectable hepatocellular carcinoma in Thailand

Chanchai Charonpongsuntorn, Suebpong Tanasanvimon, Krittiya Korphaisarn, Songwit Payapwattanawong et autres

th (code pays fourni par la source)